HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Distinct cellular responses induced by saporin and a transferrin-saporin conjugate in two different human glioblastoma cell lines.

Abstract
Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults, with a median survival of ~12-18 months post-diagnosis. GBM usually recurs within 12 months post-resection, with poor prognosis. Thus, novel therapeutic strategies to target and kill GBM cells are urgently needed. The marked difference of tumour cells with respect to normal brain cells renders glioblastoma a good candidate for selective targeted therapies. Recent experimental strategies focus on over expressed cell surface receptors. Targeted toxins represent a new class of selective molecules composed by a potent protein toxin and a carrier ligand. Targeted toxins approaches against glioblastoma were under investigation in phase I and II clinical trials with several immunotoxins (IT)/ligand toxins such as IL4-Pseudomonas aeruginosa exotoxin A (IL4-PE, NBI-3001), tumour growth factor fused to PE38, a shorter PE variant, (TGF)alpha-TP-38, IL13-PE38, and a transferrin-C diphtheriae toxin mutant (Tf-CRM107). In this work, we studied the effects of the plant ribosome-inactivating saporin and of its chimera transferrin-saporin against two different GBM cell lines. The data obtained here indicate that cell proliferation is affected by the toxin treatments but that different mechanisms are used, directly linked to the presence of an active or inactive p53. A model is proposed for these alternative intracellular pathways.
AuthorsA Cimini, S Mei, E Benedetti, G Laurenti, I Koutris, B Cinque, M G Cifone, R Galzio, G Pitari, L Di Leandro, F Giansanti, A Lombardi, M S Fabbrini, R Ippoliti
JournalJournal of cellular physiology (J Cell Physiol) Vol. 227 Issue 3 Pg. 939-51 (Mar 2012) ISSN: 1097-4652 [Electronic] United States
PMID21503892 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 Wiley Periodicals, Inc.
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Nanoconjugates
  • Ribosome Inactivating Proteins, Type 1
  • Transferrin
  • Tumor Suppressor Protein p53
  • Saporins
Topics
  • Antineoplastic Agents, Phytogenic (pharmacology)
  • Apoptosis (drug effects)
  • Brain Neoplasms (drug therapy, metabolism, pathology)
  • Cell Line, Tumor
  • Clinical Trials as Topic (methods)
  • Drug Design
  • Glioblastoma (drug therapy, metabolism, pathology)
  • Humans
  • Nanoconjugates (toxicity)
  • Ribosome Inactivating Proteins, Type 1 (genetics, toxicity)
  • Saporins
  • Transferrin (genetics, toxicity)
  • Tumor Suppressor Protein p53 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: